The University of Southampton
University of Southampton Institutional Repository

Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity

Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity
Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity

Broadly neutralizing antibodies (bNAbs) isolated from HIV-1 infected donors are vaccine paradigms. These bNAbs recognize envelope glycoprotein trimers that carry 75-90 oligomannose and complex-type glycans. Although bNAbs and their precursors must navigate past glycans, they usually also make some glycan contacts. Glycan-modified vaccines may therefore be useful to initiate and guide bNAb development. Here, we describe two ways to modify Env glycans for possible vaccine use: 1) using a cocktail of glycosidases (termed "NGAF3" (Neuraminidase, β-Galactosidase, N-Acetylglucosaminidase, endoglycosidase F3 (endo F3)) to deplete complex glycans to try to minimize bNAb-glycan clashes and 2) co-expressing β-1,4-galactosyltransferase 1 (B4G) and β-galactoside α-2,6 sialyltransferase 1 (ST6) during Env biosynthesis, creating bNAb-preferred glycan structures. Mass spectrometry revealed that NGAF3 removed glycan heads at 3/7 sites occupied by complex glycans. B4G overexpression resulted in hybrid glycan development whenever complex glycans were closely spaced. The glycan at position 611 in of Env's gp41 transmembrane subunit was uniquely isolated from the effects of both endo F3 and B4G. B4G and ST6 co-expression increased hybrid and sialylated glycan abundance, reducing glycan complexity. In rabbit vaccinations, B4G + ST6 virus-like particles (VLPs) induced less frequent, weaker titer NAbs, implying that ST6-mediated increased Env charge dampens vaccine antibodies. In some cases, vaccine sera preferentially neutralized B4G + ST6-modified pseudovirus. HIV-1+ donor plasma NAbs were generally more effective against B4G + ST6 modified pseudovirus, suggesting a preference for less complex and/or α-2,6 sialylated Env trimers. Collectively, our data suggest that B4G and ST6 Env modifications are best suited for intermediate or late vaccine shots.

AIDS Vaccines/immunology, Animals, Antibodies, Neutralizing/immunology, HIV Antibodies/immunology, HIV-1/immunology, Humans, Polysaccharides/immunology, Rabbits, env Gene Products, Human Immunodeficiency Virus/immunology
0959-6658
D'Addabbo, Alessio
ae2358c9-d733-4c7f-aaf3-b8b52b7cb810
Tong, Tommy
1e075548-7dd2-4bda-afd5-266637cc7077
Crooks, Emma T.
bd118eef-dff1-4e2a-affa-e87555024f43
Osawa, Keiko
a11c8599-df11-4cd1-af70-68e5f2baea18
Xu, Jiamin
68b5f3f7-8e0a-49dc-9f6f-3e330ced8bd7
Thomas, Alyssa
d8348a9c-9183-49bd-b394-8069a2fa6add
Allen, Joel D.
c873d886-2a66-475b-ae04-57a10b37e716
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Binley, James M.
e71790e2-16d5-4acf-8bfc-2266a4fbfeb1
D'Addabbo, Alessio
ae2358c9-d733-4c7f-aaf3-b8b52b7cb810
Tong, Tommy
1e075548-7dd2-4bda-afd5-266637cc7077
Crooks, Emma T.
bd118eef-dff1-4e2a-affa-e87555024f43
Osawa, Keiko
a11c8599-df11-4cd1-af70-68e5f2baea18
Xu, Jiamin
68b5f3f7-8e0a-49dc-9f6f-3e330ced8bd7
Thomas, Alyssa
d8348a9c-9183-49bd-b394-8069a2fa6add
Allen, Joel D.
c873d886-2a66-475b-ae04-57a10b37e716
Crispin, Max
cd980957-0943-4b89-b2b2-710f01f33bc9
Binley, James M.
e71790e2-16d5-4acf-8bfc-2266a4fbfeb1

D'Addabbo, Alessio, Tong, Tommy, Crooks, Emma T., Osawa, Keiko, Xu, Jiamin, Thomas, Alyssa, Allen, Joel D., Crispin, Max and Binley, James M. (2024) Impact of glycan depletion, glycan debranching and increased glycan charge on HIV-1 neutralization sensitivity and immunogenicity. Glycobiology, 34 (11), [cwae063]. (doi:10.1093/glycob/cwae063).

Record type: Article

Abstract

Broadly neutralizing antibodies (bNAbs) isolated from HIV-1 infected donors are vaccine paradigms. These bNAbs recognize envelope glycoprotein trimers that carry 75-90 oligomannose and complex-type glycans. Although bNAbs and their precursors must navigate past glycans, they usually also make some glycan contacts. Glycan-modified vaccines may therefore be useful to initiate and guide bNAb development. Here, we describe two ways to modify Env glycans for possible vaccine use: 1) using a cocktail of glycosidases (termed "NGAF3" (Neuraminidase, β-Galactosidase, N-Acetylglucosaminidase, endoglycosidase F3 (endo F3)) to deplete complex glycans to try to minimize bNAb-glycan clashes and 2) co-expressing β-1,4-galactosyltransferase 1 (B4G) and β-galactoside α-2,6 sialyltransferase 1 (ST6) during Env biosynthesis, creating bNAb-preferred glycan structures. Mass spectrometry revealed that NGAF3 removed glycan heads at 3/7 sites occupied by complex glycans. B4G overexpression resulted in hybrid glycan development whenever complex glycans were closely spaced. The glycan at position 611 in of Env's gp41 transmembrane subunit was uniquely isolated from the effects of both endo F3 and B4G. B4G and ST6 co-expression increased hybrid and sialylated glycan abundance, reducing glycan complexity. In rabbit vaccinations, B4G + ST6 virus-like particles (VLPs) induced less frequent, weaker titer NAbs, implying that ST6-mediated increased Env charge dampens vaccine antibodies. In some cases, vaccine sera preferentially neutralized B4G + ST6-modified pseudovirus. HIV-1+ donor plasma NAbs were generally more effective against B4G + ST6 modified pseudovirus, suggesting a preference for less complex and/or α-2,6 sialylated Env trimers. Collectively, our data suggest that B4G and ST6 Env modifications are best suited for intermediate or late vaccine shots.

Text
cwae063 - Accepted Manuscript
Restricted to Repository staff only until 30 September 2025.
Request a copy

More information

Accepted/In Press date: 7 August 2024
e-pub ahead of print date: 8 August 2024
Published date: 30 September 2024
Keywords: AIDS Vaccines/immunology, Animals, Antibodies, Neutralizing/immunology, HIV Antibodies/immunology, HIV-1/immunology, Humans, Polysaccharides/immunology, Rabbits, env Gene Products, Human Immunodeficiency Virus/immunology

Identifiers

Local EPrints ID: 495788
URI: http://eprints.soton.ac.uk/id/eprint/495788
ISSN: 0959-6658
PURE UUID: 3e39f28b-bd8a-4a1e-b764-2c9994cbfc06
ORCID for Alessio D'Addabbo: ORCID iD orcid.org/0000-0003-2542-6465
ORCID for Max Crispin: ORCID iD orcid.org/0000-0002-1072-2694

Catalogue record

Date deposited: 22 Nov 2024 17:44
Last modified: 23 Nov 2024 02:53

Export record

Altmetrics

Contributors

Author: Tommy Tong
Author: Emma T. Crooks
Author: Keiko Osawa
Author: Jiamin Xu
Author: Alyssa Thomas
Author: Joel D. Allen
Author: Max Crispin ORCID iD
Author: James M. Binley

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×